CD40LG and neoplasm: A large phase III trial tested mature monocyte-derived dendritic cells, co-electroporated with amplified tumor RNA and CD40L RNA (Rocapuldencel-T) as an intervention in combination with standard of care (SOC) for treatment of patients with metastatic renal cell carcinoma (NCT01582672).